Morgan Stanley Upgrades Ascendis Pharma A/S (NASDAQ:ASND) to "Overweight"

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) was upgraded by equities research analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating in a report released on Monday,Benzinga reports. The brokerage currently has a $250.00 price target on the biotechnology company's stock, up from their previous price target of $180.00. Morgan Stanley's price objective points to a potential upside of 45.30% from the company's previous close.

A number of other analysts have also recently commented on ASND. Wedbush lifted their target price on shares of Ascendis Pharma A/S from $181.00 to $212.00 and gave the stock an "outperform" rating in a research note on Friday. Cantor Fitzgerald lifted their price objective on shares of Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 25th. Royal Bank of Canada upped their target price on Ascendis Pharma A/S from $205.00 to $210.00 and gave the company an "outperform" rating in a research report on Friday. The Goldman Sachs Group lifted their price target on Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a research report on Thursday, February 13th. Finally, Evercore ISI increased their price objective on Ascendis Pharma A/S from $260.00 to $280.00 and gave the company an "outperform" rating in a report on Friday. One research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company's stock. According to MarketBeat, Ascendis Pharma A/S currently has an average rating of "Moderate Buy" and an average price target of $216.07.

Ascendis Pharma A/S Trading Up 2.7 %

Shares of ASND opened at $172.06 on Monday. The firm has a market cap of $10.49 billion, a PE ratio of -24.23 and a beta of 0.41. Ascendis Pharma A/S has a 12 month low of $111.09 and a 12 month high of $183.00. The stock has a fifty day moving average price of $155.31 and a 200-day moving average price of $140.42.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) EPS for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.10). The business had revenue of $123.97 million during the quarter, compared to the consensus estimate of $98.56 million. As a group, research analysts forecast that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Institutional Investors Weigh In On Ascendis Pharma A/S

Hedge funds have recently bought and sold shares of the stock. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Ascendis Pharma A/S during the 4th quarter valued at approximately $28,000. Wilmington Savings Fund Society FSB purchased a new position in Ascendis Pharma A/S in the third quarter valued at $30,000. Jones Financial Companies Lllp raised its position in shares of Ascendis Pharma A/S by 394.0% in the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock worth $34,000 after acquiring an additional 197 shares during the period. Blue Trust Inc. boosted its stake in shares of Ascendis Pharma A/S by 415.2% during the 4th quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock worth $56,000 after acquiring an additional 328 shares in the last quarter. Finally, GAMMA Investing LLC grew its position in shares of Ascendis Pharma A/S by 58.0% during the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock valued at $80,000 after acquiring an additional 214 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.